SlideShare a Scribd company logo
1 of 4
Download to read offline
KSB Pumps 
Weak margin performance 
October 27, 2014 
600 
550 
500 
450 
400 
350 
300 
250 
200 
150 
Oct‐13 
Dec‐13 
Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that 
the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision. 
Please refer to important disclosures and disclaimers at the end of the report 
Q3CY14 Result Update 
Kunal Sheth 
kunalsheth@plindia.com 
+91‐22‐66322257 
Samir Bendre 
samirbendre@plindia.com 
+91‐22‐66322256 
Rating BUY 
Price Rs512 
Target Price Rs563 
Implied Upside 10.0% 
Sensex 26,851 
Nifty 8,015 
(Prices as on October 23, 2014) 
Trading data 
Market Cap. (Rs bn) 17.8 
Shares o/s (m) 34.8 
3M Avg. Daily value (Rs m) 19.4 
Major shareholders 
Promoters 66.41% 
Foreign 2.58% 
Domestic Inst. 14.18% 
Public & Other 16.83% 
Stock Performance 
(%) 1M 6M 12M 
Absolute (5.7) 51.8 132.8 
Relative (6.1) 34.4 103.2 
How we differ from Consensus 
EPS (Rs) PL Cons. % Diff. 
2014 21.6 20.2 7.0 
2015 25.6 24.3 5.2 
Price Performance (RIC: KSBP.BO, BB: KSB IN) 
Source: Bloomberg 
Feb‐14 
Apr‐14 
Jun‐14 
Aug‐14 
(Rs) 
KSB Pumps reported PAT at Rs179m, flat YoY, lower than our estimate, while sales 
were in line with our estimate (up 5.7% YoY). Weaker‐than‐expected margins were 
due to unfavourable mix and losses in the valve segment. KSB’s products have an 
application across a wide spectrum of industries which makes it the key beneficiary 
in the event of a turn in cycle. We expect the stock to deliver earnings CAGR of 22% 
over CY13‐15E. Maintain ‘BUY’. 
 Sales in line ‐ Margins take a hit: KSB reported sales at Rs1.98bn, up 5.7% YoY 
(PLe: Rs2bn). While sales in the Pump segment was up 5.7% YoY to Rs1.64bn, 
sales in the Valve segment showed growth (up 2.4% YoY) at Rs327m after four 
quarters of de‐growth. EBITDA margins dipped 240bps YoY to 13.6% (PLe: 
14.9%) mainly on account of high base last year and unfavourable mix. Gross 
margin dipped 70bps YoY to 55%, employee cost was up 13% YoY to Rs315m 
and other expense increased 10% YoY to Rs508m. EBIT margin for the Pump 
segment dipped by 74bps YoY to 14.7%, while Valve segment reported EBIT loss 
of Rs13m. Other income was up 129% YoY to Rs80m. Strong growth in other 
income helped post a flat PAT at Rs179m (PLe: Rs195m). 
 Outlook and Valuation: The stock is trading at 20x CY15E earnings. KSB has a 
strong product portfolio and is a dominant market player. The company is likely 
to benefit from an expected pick‐up in Power and Oil & Gas capex and increased 
focus on Water and Irrigation capex by the new government. The market 
movement towards energy‐efficient pumps should help organized players and 
benefit KSB. Strong balance sheet and cash flow provides additional comfort. 
We maintain ‘BUY’ rating on stock. 
Key f inancials (Y/e December) 2012 2013 2014E 2015E 
Revenues (Rs m) 7,224 7,313 7,621 8,383 
Growth (%) (3.6) 1.2 4.2 10.0 
EBITDA (Rs m) 911 1,006 1,101 1,292 
PAT (Rs m) 580 598 753 890 
EPS (Rs) 16.7 17.2 21.6 25.6 
Growth (%) 35.0 3.0 26.1 18.1 
Net DPS (Rs) 5.5 6.0 7.0 7.0 
Profitability & Valuation 2012 2013 2014E 2015E 
EBITDA margin (%) 12.6 13.8 14.4 15.4 
RoE (%) 14.2 13.3 15.2 16.4 
RoCE (%) 13.7 13.2 15.0 16.2 
EV / sales (x) 2.4 2.3 2.2 1.9 
EV / EBITDA (x) 18.6 16.7 14.9 12.2 
PE (x) 30.7 29.8 23.6 20.0 
P / BV (x) 4.2 3.8 3.4 3.1 
Net dividend yield (%) 1.1 1.2 1.4 1.4 
Source: Company Data; PL Research
KSB Pumps 
Exhibit 1: Q3CY14 Result Overview (Rs m) 
Y/e March Q3CY14 Q3CY13 YoY gr. (%) Q2CY13 9MFY14 9MFY13 YoY gr. (%) 
Net Sales 1,989 1,882 5.7 1,994 5,716 5,492 4.1 
RM cost 896 860 4.2 926 2,599 2,556 1.7 
% of Net Sales 45.0 45.7 46.4 45.5 46.5 
Employee Costs 315 278 13.5 323 949 844 12.4 
% of Net Sales 15.8 14.8 16.2 16.6 15.4 
Other Costs 508 463 9.7 452 1,353 1,304 3.8 
% of Net Sales 25.5 24.6 22.7 23.7 23.7 
Cost of Goods Sold 1,719 1,600 7.4 1,700 4,901 4,704 4.2 
% of Net Sales 86.4 85.0 85.3 85.7 85.6 
EBITDA 270 302 (10.5) 293 815 788 3.4 
% of Sales 13.6 16.1 14.7 14.3 14.4 
Depreciation 69 68 2.2 68 204 195 4.6 
Other Income 80 35 129.1 94 220 138 59.4 
EBIT 282 270 4.5 319 831 731 13.6 
Interest 13 6 115.5 3 18 23 (23.6) 
PBT 269 264 2.0 316 813 708 14.8 
Total Tax 90 85 6.7 92 259 219 18.4 
ETR % 33.6 32.1 29.0 31.8 30.9 
Reported PAT 179 179 (0.2) 225 555 490 13.2 
Adj PAT 179 179 (0.2) 225 555 490 13.2 
Source: Company Data, PL Research 
October 27, 2014 2
KSB Pumps 
Income Statement (Rs m) 
Y/e December 2012 2013 2014E 2015E 
Net Revenue 7,224 7,313 7,621 8,383 
Raw Material Expenses 3,582 3,326 3,353 3,688 
Gross Profit 3,642 3,988 4,268 4,694 
Employee Cost 1,036 1,101 1,156 1,271 
Other Expenses 1,695 1,881 2,011 2,131 
EBITDA 911 1,006 1,101 1,292 
Depr. & Amortization 235 265 290 315 
Net Interest 52 26 25 25 
Other Income 184 162 291 320 
Profit before Tax 807 876 1,076 1,271 
Total Tax 226 279 323 381 
Profit after Tax 580 598 753 890 
Ex‐Od items / Min. Int. — — 1 — 
Adj. PAT 580 598 753 890 
Avg. Shares O/S (m) 34.8 34.8 34.8 34.8 
EPS (Rs.) 16.7 17.2 21.6 25.6 
Cash Flow Abstract (Rs m) 
Y/e December 2012 2013 2014E 2015E 
C/F from Operations 1,246 729 955 1,036 
C/F from Investing (390) (300) (300) (300) 
C/F from Financing (677) (209) (244) (244) 
Inc. / Dec. in Cash 180 220 412 493 
Opening Cash 817 1,002 1,222 1,634 
Closing Cash 997 1,222 1,634 2,127 
FCFF 1,082 355 655 736 
FCFE 618 355 655 736 
Key Financial Metrics 
Y/e December 2012 2013 2014E 2015E 
Growth 
Revenue (%) (3.6) 1.2 4.2 10.0 
EBITDA (%) 27.9 10.4 9.4 17.4 
PAT (%) 35.0 3.0 26.1 18.1 
EPS (%) 35.0 3.0 26.1 18.1 
Profitability 
EBITDA Margin (%) 12.6 13.8 14.4 15.4 
PAT Margin (%) 8.0 8.2 9.9 10.6 
RoCE (%) 13.7 13.2 15.0 16.2 
RoE (%) 14.2 13.3 15.2 16.4 
Balance Sheet 
Net Debt : Equity (0.2) (0.2) (0.3) (0.4) 
Net Wrkng Cap. (days) — — — — 
Valuation 
PER (x) 30.7 29.8 23.6 20.0 
P / B (x) 4.2 3.8 3.4 3.1 
EV / EBITDA (x) 18.6 16.7 14.9 12.2 
EV / Sales (x) 2.4 2.3 2.2 1.9 
Earnings Quality 
Eff. Tax Rate 28.1 31.8 30.0 30.0 
Other Inc / PBT 22.8 18.4 27.0 25.2 
Eff. Depr. Rate (%) 6.5 6.8 6.9 7.0 
FCFE / PAT 106.6 59.5 87.0 82.7 
Source: Company Data, PL Research. 
Balance Sheet Abstract (Rs m) 
Y/e December 2012 2013 2014E 2015E 
Shareholder's Funds 4,259 4,730 5,181 5,664 
Total Debt 169 169 169 169 
Other Liabilities — — — — 
Total Liabilities 4,427 4,898 5,350 5,832 
Net Fixed Assets 1,852 1,887 1,896 1,604 
Goodwill — — — — 
Investments 64 64 64 64 
Net Current Assets 2,438 2,873 3,315 4,090 
Cash & Equivalents 1,002 1,230 1,584 2,190 
Other Current Assets 4,130 4,148 4,320 4,748 
Current Liabilities 2,695 2,505 2,589 2,848 
Other Assets 75 75 75 75 
Total Assets 4,428 4,898 5,350 5,832 
Quarterly Financials (Rs m) 
Y/e December Q4CY14 Q1CY14 Q2CY14 Q3CY14 
Net Revenue 1,795 1,734 1,994 1,989 
EBITDA 217 251 293 270 
% of revenue 11.9 14.5 14.7 13.6 
Depr. & Amortization 70 67 68 69 
Net Interest 3 2 3 13 
Other Income 24 46 94 80 
Profit before Tax 168 228 316 269 
Total Tax 60 77 92 90 
Profit after Tax 108 151 225 179 
Adj. PAT 108 151 225 179 
Source: Company Data, PL Research. 
October 27, 2014 3
KSB Pumps 
Prabhudas Lilladher Pvt. Ltd. 
3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai‐400 018, India 
Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 
Rating Distribution of Research Coverage 
31.7% 
51.9% 
16.3% 
0.0% 
60% 
50% 
40% 
30% 
20% 
10% 
0% 
BUY Accumulate Reduce Sell 
% of Total Coverage 
PL’s Recommendation Nomenclature 
BUY : Over 15% Outperformance to Sensex over 12‐months Accumulate : Outperformance to Sensex over 12‐months 
Reduce : Underperformance to Sensex over 12‐months Sell : Over 15% underperformance to Sensex over 12‐months 
Trading Buy : Over 10% absolute upside in 1‐month Trading Sell : Over 10% absolute decline in 1‐month 
Not Rated (NR) : No specific call on the stock Under Review (UR) : Rating likely to change shortly 
This document has been prepared by the Research Division of Prabhudas Lilladher Pvt. Ltd. Mumbai, India (PL) and is meant for use by the recipient only as 
information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be 
considered or taken as an offer to sell or a solicitation to buy or sell any security. 
The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy 
or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, 
statements and opinion given, made available or expressed herein or for any omission therein. 
Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The 
suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an 
independent expert/advisor. 
Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or 
engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. 
We may from time to time solicit or perform investment banking or other services for any company mentioned in this document. 
October 27, 2014 4

More Related Content

What's hot

Liberty Bank Research Note - Q1 2014 Results
Liberty Bank Research Note - Q1 2014 ResultsLiberty Bank Research Note - Q1 2014 Results
Liberty Bank Research Note - Q1 2014 ResultsLiberty Securities
 
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA Securities
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA SecuritiesSetco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA Securities
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA SecuritiesIndiaNotes.com
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 August 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 August 2015EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 August 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 August 2015Epic Research Singapore
 
Larsen & Toubro: Strong order flow momentum; Maintain buy - Prabhudas Lilladher
Larsen & Toubro: Strong order flow momentum; Maintain buy - Prabhudas LilladherLarsen & Toubro: Strong order flow momentum; Maintain buy - Prabhudas Lilladher
Larsen & Toubro: Strong order flow momentum; Maintain buy - Prabhudas LilladherIndiaNotes.com
 
Zee 1QFY18
Zee 1QFY18Zee 1QFY18
Zee 1QFY18Mohit Jn
 
Mastek 1QFY18
Mastek 1QFY18Mastek 1QFY18
Mastek 1QFY18Mohit Jn
 
Financial Statement Analysis Powerpoint Presentation Slides
Financial Statement Analysis Powerpoint Presentation SlidesFinancial Statement Analysis Powerpoint Presentation Slides
Financial Statement Analysis Powerpoint Presentation SlidesSlideTeam
 
HGSL 1QFY18
HGSL 1QFY18HGSL 1QFY18
HGSL 1QFY18Mohit Jn
 
Mindtree 1QFY18
Mindtree 1QFY18Mindtree 1QFY18
Mindtree 1QFY18Mohit Jn
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 27 March 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 27 March 2015EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 27 March 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 27 March 2015Epic Research Singapore
 
Persistent 1QFY18
Persistent 1QFY18Persistent 1QFY18
Persistent 1QFY18Mohit Jn
 
GuessBox Financial Model 2017
GuessBox Financial Model 2017GuessBox Financial Model 2017
GuessBox Financial Model 2017GuessBox
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 February 2016
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 February 2016EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 February 2016
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 February 2016Nicole Chan
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 16 February 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 16 February 2015EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 16 February 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 16 February 2015Epic Research Singapore
 
Example Presentation Of Financial Reports PowerPoint Presentation Slides
Example Presentation Of Financial Reports PowerPoint Presentation Slides Example Presentation Of Financial Reports PowerPoint Presentation Slides
Example Presentation Of Financial Reports PowerPoint Presentation Slides SlideTeam
 
Balance sheet of Bajaj auto limited
Balance sheet of Bajaj auto limitedBalance sheet of Bajaj auto limited
Balance sheet of Bajaj auto limitedNirmal Shanmugam
 

What's hot (20)

Liberty Bank Research Note - Q1 2014 Results
Liberty Bank Research Note - Q1 2014 ResultsLiberty Bank Research Note - Q1 2014 Results
Liberty Bank Research Note - Q1 2014 Results
 
캐피탈 영문
캐피탈 영문캐피탈 영문
캐피탈 영문
 
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA Securities
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA SecuritiesSetco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA Securities
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA Securities
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 August 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 August 2015EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 August 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 August 2015
 
Larsen & Toubro: Strong order flow momentum; Maintain buy - Prabhudas Lilladher
Larsen & Toubro: Strong order flow momentum; Maintain buy - Prabhudas LilladherLarsen & Toubro: Strong order flow momentum; Maintain buy - Prabhudas Lilladher
Larsen & Toubro: Strong order flow momentum; Maintain buy - Prabhudas Lilladher
 
Zee 1QFY18
Zee 1QFY18Zee 1QFY18
Zee 1QFY18
 
Excel Model of Trading Firm
Excel Model of Trading FirmExcel Model of Trading Firm
Excel Model of Trading Firm
 
Mastek 1QFY18
Mastek 1QFY18Mastek 1QFY18
Mastek 1QFY18
 
Financial Statement Analysis Powerpoint Presentation Slides
Financial Statement Analysis Powerpoint Presentation SlidesFinancial Statement Analysis Powerpoint Presentation Slides
Financial Statement Analysis Powerpoint Presentation Slides
 
Csl daily market update 18082015
Csl daily market update 18082015Csl daily market update 18082015
Csl daily market update 18082015
 
HGSL 1QFY18
HGSL 1QFY18HGSL 1QFY18
HGSL 1QFY18
 
Mindtree 1QFY18
Mindtree 1QFY18Mindtree 1QFY18
Mindtree 1QFY18
 
카드3분기 영문pt
카드3분기 영문pt카드3분기 영문pt
카드3분기 영문pt
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 27 March 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 27 March 2015EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 27 March 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 27 March 2015
 
Persistent 1QFY18
Persistent 1QFY18Persistent 1QFY18
Persistent 1QFY18
 
GuessBox Financial Model 2017
GuessBox Financial Model 2017GuessBox Financial Model 2017
GuessBox Financial Model 2017
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 February 2016
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 February 2016EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 February 2016
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 05 February 2016
 
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 16 February 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 16 February 2015EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 16 February 2015
EPIC RESEARCH SINGAPORE - Daily SGX Singapore report of 16 February 2015
 
Example Presentation Of Financial Reports PowerPoint Presentation Slides
Example Presentation Of Financial Reports PowerPoint Presentation Slides Example Presentation Of Financial Reports PowerPoint Presentation Slides
Example Presentation Of Financial Reports PowerPoint Presentation Slides
 
Balance sheet of Bajaj auto limited
Balance sheet of Bajaj auto limitedBalance sheet of Bajaj auto limited
Balance sheet of Bajaj auto limited
 

Similar to KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher

Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15EIndiaNotes.com
 
Pidilite Ind: Reports 11% volume growth in a tough operating environment - Pr...
Pidilite Ind: Reports 11% volume growth in a tough operating environment - Pr...Pidilite Ind: Reports 11% volume growth in a tough operating environment - Pr...
Pidilite Ind: Reports 11% volume growth in a tough operating environment - Pr...IndiaNotes.com
 
Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins
 Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins
Dr. Reddy's 1FY15: Strong sales in key markets drive growth, marginsIndiaNotes.com
 
Pl shree cement_04may15[1]
Pl shree cement_04may15[1]Pl shree cement_04may15[1]
Pl shree cement_04may15[1]IndiaNotes.com
 
ACC: Buy for a target of Rs1650
ACC: Buy for a target of Rs1650ACC: Buy for a target of Rs1650
ACC: Buy for a target of Rs1650IndiaNotes.com
 
State Bank of India: Absolute valuations, accumulate - Prabhudas Lilladher
State Bank of India: Absolute valuations, accumulate - Prabhudas LilladherState Bank of India: Absolute valuations, accumulate - Prabhudas Lilladher
State Bank of India: Absolute valuations, accumulate - Prabhudas LilladherIndiaNotes.com
 
Voltas Visit Update: Muted near-term outlook - Prabhudas Lilladher
Voltas Visit Update: Muted near-term outlook - Prabhudas LilladherVoltas Visit Update: Muted near-term outlook - Prabhudas Lilladher
Voltas Visit Update: Muted near-term outlook - Prabhudas LilladherIndiaNotes.com
 
Buy Britannia Industries for a target of Rs1110 - Prabhudas Lilladher
Buy Britannia Industries for a target of Rs1110 - Prabhudas LilladherBuy Britannia Industries for a target of Rs1110 - Prabhudas Lilladher
Buy Britannia Industries for a target of Rs1110 - Prabhudas LilladherIndiaNotes.com
 
Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015IndiaNotes.com
 
MindTree: Prospect looks upbeat; buy
MindTree: Prospect looks upbeat; buyMindTree: Prospect looks upbeat; buy
MindTree: Prospect looks upbeat; buyIndiaNotes.com
 
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQMahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQIndiaNotes.com
 
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangQ2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangIndiaNotes.com
 
Hindustan Zinc: Still lot of juice left; buy
Hindustan Zinc: Still lot of juice left; buyHindustan Zinc: Still lot of juice left; buy
Hindustan Zinc: Still lot of juice left; buyIndiaNotes.com
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15IndiaNotes.com
 
Sun Pharma: Compelling valuation post stake sale of Daiichi; Buy
Sun Pharma: Compelling valuation post stake sale of Daiichi; BuySun Pharma: Compelling valuation post stake sale of Daiichi; Buy
Sun Pharma: Compelling valuation post stake sale of Daiichi; BuyIndiaNotes.com
 
Crompton Greaves: Ideally places to benefit from an improved economic growth,...
Crompton Greaves: Ideally places to benefit from an improved economic growth,...Crompton Greaves: Ideally places to benefit from an improved economic growth,...
Crompton Greaves: Ideally places to benefit from an improved economic growth,...IndiaNotes.com
 
JK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buy
JK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buyJK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buy
JK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buyIndiaNotes.com
 
Stock Tip: Buy this stock for a target of Rs270
Stock Tip: Buy this stock for a target of Rs270Stock Tip: Buy this stock for a target of Rs270
Stock Tip: Buy this stock for a target of Rs270IndiaNotes.com
 
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buyWelspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buyIndiaNotes.com
 
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presence
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presencePersistent Systems: Acquired RGen Solutions, Strengthening OPD presence
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presenceIndiaNotes.com
 

Similar to KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher (20)

Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15E
 
Pidilite Ind: Reports 11% volume growth in a tough operating environment - Pr...
Pidilite Ind: Reports 11% volume growth in a tough operating environment - Pr...Pidilite Ind: Reports 11% volume growth in a tough operating environment - Pr...
Pidilite Ind: Reports 11% volume growth in a tough operating environment - Pr...
 
Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins
 Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins
Dr. Reddy's 1FY15: Strong sales in key markets drive growth, margins
 
Pl shree cement_04may15[1]
Pl shree cement_04may15[1]Pl shree cement_04may15[1]
Pl shree cement_04may15[1]
 
ACC: Buy for a target of Rs1650
ACC: Buy for a target of Rs1650ACC: Buy for a target of Rs1650
ACC: Buy for a target of Rs1650
 
State Bank of India: Absolute valuations, accumulate - Prabhudas Lilladher
State Bank of India: Absolute valuations, accumulate - Prabhudas LilladherState Bank of India: Absolute valuations, accumulate - Prabhudas Lilladher
State Bank of India: Absolute valuations, accumulate - Prabhudas Lilladher
 
Voltas Visit Update: Muted near-term outlook - Prabhudas Lilladher
Voltas Visit Update: Muted near-term outlook - Prabhudas LilladherVoltas Visit Update: Muted near-term outlook - Prabhudas Lilladher
Voltas Visit Update: Muted near-term outlook - Prabhudas Lilladher
 
Buy Britannia Industries for a target of Rs1110 - Prabhudas Lilladher
Buy Britannia Industries for a target of Rs1110 - Prabhudas LilladherBuy Britannia Industries for a target of Rs1110 - Prabhudas Lilladher
Buy Britannia Industries for a target of Rs1110 - Prabhudas Lilladher
 
Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015Prabhudas lilladher techmahindra_29june_2015
Prabhudas lilladher techmahindra_29june_2015
 
MindTree: Prospect looks upbeat; buy
MindTree: Prospect looks upbeat; buyMindTree: Prospect looks upbeat; buy
MindTree: Prospect looks upbeat; buy
 
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQMahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
Mahindra Financial result update: 4QFY15 PAT up 7% YoY and 144% QoQ
 
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangQ2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
 
Hindustan Zinc: Still lot of juice left; buy
Hindustan Zinc: Still lot of juice left; buyHindustan Zinc: Still lot of juice left; buy
Hindustan Zinc: Still lot of juice left; buy
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15
 
Sun Pharma: Compelling valuation post stake sale of Daiichi; Buy
Sun Pharma: Compelling valuation post stake sale of Daiichi; BuySun Pharma: Compelling valuation post stake sale of Daiichi; Buy
Sun Pharma: Compelling valuation post stake sale of Daiichi; Buy
 
Crompton Greaves: Ideally places to benefit from an improved economic growth,...
Crompton Greaves: Ideally places to benefit from an improved economic growth,...Crompton Greaves: Ideally places to benefit from an improved economic growth,...
Crompton Greaves: Ideally places to benefit from an improved economic growth,...
 
JK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buy
JK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buyJK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buy
JK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buy
 
Stock Tip: Buy this stock for a target of Rs270
Stock Tip: Buy this stock for a target of Rs270Stock Tip: Buy this stock for a target of Rs270
Stock Tip: Buy this stock for a target of Rs270
 
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buyWelspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
 
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presence
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presencePersistent Systems: Acquired RGen Solutions, Strengthening OPD presence
Persistent Systems: Acquired RGen Solutions, Strengthening OPD presence
 

More from IndiaNotes.com

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15IndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesIndiaNotes.com
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoIndiaNotes.com
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityIndiaNotes.com
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16IndiaNotes.com
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtIndiaNotes.com
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...IndiaNotes.com
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...IndiaNotes.com
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CAREIndiaNotes.com
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...IndiaNotes.com
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16EIndiaNotes.com
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...IndiaNotes.com
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyIndiaNotes.com
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndiaNotes.com
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyIndiaNotes.com
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetIndiaNotes.com
 

More from IndiaNotes.com (20)

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debt
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
 

KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher

  • 1. KSB Pumps Weak margin performance October 27, 2014 600 550 500 450 400 350 300 250 200 150 Oct‐13 Dec‐13 Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision. Please refer to important disclosures and disclaimers at the end of the report Q3CY14 Result Update Kunal Sheth kunalsheth@plindia.com +91‐22‐66322257 Samir Bendre samirbendre@plindia.com +91‐22‐66322256 Rating BUY Price Rs512 Target Price Rs563 Implied Upside 10.0% Sensex 26,851 Nifty 8,015 (Prices as on October 23, 2014) Trading data Market Cap. (Rs bn) 17.8 Shares o/s (m) 34.8 3M Avg. Daily value (Rs m) 19.4 Major shareholders Promoters 66.41% Foreign 2.58% Domestic Inst. 14.18% Public & Other 16.83% Stock Performance (%) 1M 6M 12M Absolute (5.7) 51.8 132.8 Relative (6.1) 34.4 103.2 How we differ from Consensus EPS (Rs) PL Cons. % Diff. 2014 21.6 20.2 7.0 2015 25.6 24.3 5.2 Price Performance (RIC: KSBP.BO, BB: KSB IN) Source: Bloomberg Feb‐14 Apr‐14 Jun‐14 Aug‐14 (Rs) KSB Pumps reported PAT at Rs179m, flat YoY, lower than our estimate, while sales were in line with our estimate (up 5.7% YoY). Weaker‐than‐expected margins were due to unfavourable mix and losses in the valve segment. KSB’s products have an application across a wide spectrum of industries which makes it the key beneficiary in the event of a turn in cycle. We expect the stock to deliver earnings CAGR of 22% over CY13‐15E. Maintain ‘BUY’.  Sales in line ‐ Margins take a hit: KSB reported sales at Rs1.98bn, up 5.7% YoY (PLe: Rs2bn). While sales in the Pump segment was up 5.7% YoY to Rs1.64bn, sales in the Valve segment showed growth (up 2.4% YoY) at Rs327m after four quarters of de‐growth. EBITDA margins dipped 240bps YoY to 13.6% (PLe: 14.9%) mainly on account of high base last year and unfavourable mix. Gross margin dipped 70bps YoY to 55%, employee cost was up 13% YoY to Rs315m and other expense increased 10% YoY to Rs508m. EBIT margin for the Pump segment dipped by 74bps YoY to 14.7%, while Valve segment reported EBIT loss of Rs13m. Other income was up 129% YoY to Rs80m. Strong growth in other income helped post a flat PAT at Rs179m (PLe: Rs195m).  Outlook and Valuation: The stock is trading at 20x CY15E earnings. KSB has a strong product portfolio and is a dominant market player. The company is likely to benefit from an expected pick‐up in Power and Oil & Gas capex and increased focus on Water and Irrigation capex by the new government. The market movement towards energy‐efficient pumps should help organized players and benefit KSB. Strong balance sheet and cash flow provides additional comfort. We maintain ‘BUY’ rating on stock. Key f inancials (Y/e December) 2012 2013 2014E 2015E Revenues (Rs m) 7,224 7,313 7,621 8,383 Growth (%) (3.6) 1.2 4.2 10.0 EBITDA (Rs m) 911 1,006 1,101 1,292 PAT (Rs m) 580 598 753 890 EPS (Rs) 16.7 17.2 21.6 25.6 Growth (%) 35.0 3.0 26.1 18.1 Net DPS (Rs) 5.5 6.0 7.0 7.0 Profitability & Valuation 2012 2013 2014E 2015E EBITDA margin (%) 12.6 13.8 14.4 15.4 RoE (%) 14.2 13.3 15.2 16.4 RoCE (%) 13.7 13.2 15.0 16.2 EV / sales (x) 2.4 2.3 2.2 1.9 EV / EBITDA (x) 18.6 16.7 14.9 12.2 PE (x) 30.7 29.8 23.6 20.0 P / BV (x) 4.2 3.8 3.4 3.1 Net dividend yield (%) 1.1 1.2 1.4 1.4 Source: Company Data; PL Research
  • 2. KSB Pumps Exhibit 1: Q3CY14 Result Overview (Rs m) Y/e March Q3CY14 Q3CY13 YoY gr. (%) Q2CY13 9MFY14 9MFY13 YoY gr. (%) Net Sales 1,989 1,882 5.7 1,994 5,716 5,492 4.1 RM cost 896 860 4.2 926 2,599 2,556 1.7 % of Net Sales 45.0 45.7 46.4 45.5 46.5 Employee Costs 315 278 13.5 323 949 844 12.4 % of Net Sales 15.8 14.8 16.2 16.6 15.4 Other Costs 508 463 9.7 452 1,353 1,304 3.8 % of Net Sales 25.5 24.6 22.7 23.7 23.7 Cost of Goods Sold 1,719 1,600 7.4 1,700 4,901 4,704 4.2 % of Net Sales 86.4 85.0 85.3 85.7 85.6 EBITDA 270 302 (10.5) 293 815 788 3.4 % of Sales 13.6 16.1 14.7 14.3 14.4 Depreciation 69 68 2.2 68 204 195 4.6 Other Income 80 35 129.1 94 220 138 59.4 EBIT 282 270 4.5 319 831 731 13.6 Interest 13 6 115.5 3 18 23 (23.6) PBT 269 264 2.0 316 813 708 14.8 Total Tax 90 85 6.7 92 259 219 18.4 ETR % 33.6 32.1 29.0 31.8 30.9 Reported PAT 179 179 (0.2) 225 555 490 13.2 Adj PAT 179 179 (0.2) 225 555 490 13.2 Source: Company Data, PL Research October 27, 2014 2
  • 3. KSB Pumps Income Statement (Rs m) Y/e December 2012 2013 2014E 2015E Net Revenue 7,224 7,313 7,621 8,383 Raw Material Expenses 3,582 3,326 3,353 3,688 Gross Profit 3,642 3,988 4,268 4,694 Employee Cost 1,036 1,101 1,156 1,271 Other Expenses 1,695 1,881 2,011 2,131 EBITDA 911 1,006 1,101 1,292 Depr. & Amortization 235 265 290 315 Net Interest 52 26 25 25 Other Income 184 162 291 320 Profit before Tax 807 876 1,076 1,271 Total Tax 226 279 323 381 Profit after Tax 580 598 753 890 Ex‐Od items / Min. Int. — — 1 — Adj. PAT 580 598 753 890 Avg. Shares O/S (m) 34.8 34.8 34.8 34.8 EPS (Rs.) 16.7 17.2 21.6 25.6 Cash Flow Abstract (Rs m) Y/e December 2012 2013 2014E 2015E C/F from Operations 1,246 729 955 1,036 C/F from Investing (390) (300) (300) (300) C/F from Financing (677) (209) (244) (244) Inc. / Dec. in Cash 180 220 412 493 Opening Cash 817 1,002 1,222 1,634 Closing Cash 997 1,222 1,634 2,127 FCFF 1,082 355 655 736 FCFE 618 355 655 736 Key Financial Metrics Y/e December 2012 2013 2014E 2015E Growth Revenue (%) (3.6) 1.2 4.2 10.0 EBITDA (%) 27.9 10.4 9.4 17.4 PAT (%) 35.0 3.0 26.1 18.1 EPS (%) 35.0 3.0 26.1 18.1 Profitability EBITDA Margin (%) 12.6 13.8 14.4 15.4 PAT Margin (%) 8.0 8.2 9.9 10.6 RoCE (%) 13.7 13.2 15.0 16.2 RoE (%) 14.2 13.3 15.2 16.4 Balance Sheet Net Debt : Equity (0.2) (0.2) (0.3) (0.4) Net Wrkng Cap. (days) — — — — Valuation PER (x) 30.7 29.8 23.6 20.0 P / B (x) 4.2 3.8 3.4 3.1 EV / EBITDA (x) 18.6 16.7 14.9 12.2 EV / Sales (x) 2.4 2.3 2.2 1.9 Earnings Quality Eff. Tax Rate 28.1 31.8 30.0 30.0 Other Inc / PBT 22.8 18.4 27.0 25.2 Eff. Depr. Rate (%) 6.5 6.8 6.9 7.0 FCFE / PAT 106.6 59.5 87.0 82.7 Source: Company Data, PL Research. Balance Sheet Abstract (Rs m) Y/e December 2012 2013 2014E 2015E Shareholder's Funds 4,259 4,730 5,181 5,664 Total Debt 169 169 169 169 Other Liabilities — — — — Total Liabilities 4,427 4,898 5,350 5,832 Net Fixed Assets 1,852 1,887 1,896 1,604 Goodwill — — — — Investments 64 64 64 64 Net Current Assets 2,438 2,873 3,315 4,090 Cash & Equivalents 1,002 1,230 1,584 2,190 Other Current Assets 4,130 4,148 4,320 4,748 Current Liabilities 2,695 2,505 2,589 2,848 Other Assets 75 75 75 75 Total Assets 4,428 4,898 5,350 5,832 Quarterly Financials (Rs m) Y/e December Q4CY14 Q1CY14 Q2CY14 Q3CY14 Net Revenue 1,795 1,734 1,994 1,989 EBITDA 217 251 293 270 % of revenue 11.9 14.5 14.7 13.6 Depr. & Amortization 70 67 68 69 Net Interest 3 2 3 13 Other Income 24 46 94 80 Profit before Tax 168 228 316 269 Total Tax 60 77 92 90 Profit after Tax 108 151 225 179 Adj. PAT 108 151 225 179 Source: Company Data, PL Research. October 27, 2014 3
  • 4. KSB Pumps Prabhudas Lilladher Pvt. Ltd. 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai‐400 018, India Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 Rating Distribution of Research Coverage 31.7% 51.9% 16.3% 0.0% 60% 50% 40% 30% 20% 10% 0% BUY Accumulate Reduce Sell % of Total Coverage PL’s Recommendation Nomenclature BUY : Over 15% Outperformance to Sensex over 12‐months Accumulate : Outperformance to Sensex over 12‐months Reduce : Underperformance to Sensex over 12‐months Sell : Over 15% underperformance to Sensex over 12‐months Trading Buy : Over 10% absolute upside in 1‐month Trading Sell : Over 10% absolute decline in 1‐month Not Rated (NR) : No specific call on the stock Under Review (UR) : Rating likely to change shortly This document has been prepared by the Research Division of Prabhudas Lilladher Pvt. Ltd. Mumbai, India (PL) and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. We may from time to time solicit or perform investment banking or other services for any company mentioned in this document. October 27, 2014 4